Magrolimab is a Monoclonal Antibody owned by Gilead Sciences, and is involved in 29 clinical trials, of which 5 were completed, 22 are ongoing, and 2 are planned.

Magrolimab exhibits antibody dependent cellular phagocytosis (ADCP) and regulates the CD47-SIRP alpha (SIRPa) interaction. SIRP alpha shows adhesion to CD47 integrin associated protein. SIRP alpha (SIRPa) belong to the signal regulatory proteins family which are the regulators of leukocyte migration and phagocytosis. CD47-SIRP alpha binding initiates phosphorylation of the immunoreceptor tyrosine-based inhibition motifs present on the cytoplasmic tail of SIRPa. CD47 expression is required to protect transfused red blood cells, platelets and lymphocytes from rapid elimination by splenic macrophages. Mobilized hematopoietic stem cells increase CD47 expression to protect themselves from phagocytosis while passing through phagocyte-lined sinusoids. The drug candidate alleviates CD47-mediated suppression and promotes anti-tumour responses.

The revenue for Magrolimab is expected to reach a total of $6.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Magrolimab NPV Report.

Magrolimab was originated by Stanford University and is currently owned by Gilead Sciences.

Magrolimab Overview

Magrolimab is under development for the treatment of Hodgkin lymphoma., previously untreated, relapsed or refractory acute myelocytic leukemia and myelodysplastic syndrome, solid tumor, relapsed/refractory multiple myeloma, recurrent head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, urethral cancer, metastatic urothelial cancer, metastatic small cell lung cancer and metastatic non-small cell lung cancer, ureter cancer, breast cancer, colorectal cancer, epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer, head and neck cancer, ovarian, AML, NHL, myelodysplastic syndrome, relapsed and refractory B-cell non-Hodgkin's lymphoma, triple negative breast cancer, indolent lymphoma, metastatic transitional (urothelial) tract cancer, bladder cancer, marginal zone or follicular lymphoma, malignant primary brain tumor, metastatic colorectal cancer and atherosclerosis. It is a humanized IgG4 subclass monoclonal antibody. The drug candidate is administered through intravenous route. It acts by targeting CD47. The drug candidate is a new chemical entity.

It was also under development for diffuse large B-cell lymphoma, cutaneous T-cell lymphoma.

Gilead Sciences Overview

Gilead Sciences (Gilead) is a research-based biopharmaceutical company. It is engaged in the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency virus (HIV) infection. The company sells its products through subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East and Africa. It has manufacturing facilities in Edmonton, Alberta, Canada; Foster City, San Dimas, Oceanside, California; and Cork, Ireland among others. The company has partnerships with universities, medical research institutions and global pharmaceutical leaders to develop new drugs. Gilead is headquartered in Foster City, California, the US.

The company reported revenues of (US Dollars) US$27,305 million for the fiscal year ended December 2021 (FY2021), an increase of 10.6% over FY2020. In FY2021, the company’s operating margin was 36.3%, compared to an operating margin of 16.5% in FY2020. In FY2021, the company recorded a net margin of 22.8%, compared to a net margin of 0.5% in FY2020. The company reported revenues of US$7,042 million for the third quarter ended September 2022, an increase of 12.5% over the previous quarter.

Quick View – Magrolimab

Report Segments
  • Innovator
Drug Name
  • Magrolimab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.